Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1794 1
1845 1
1850 3
1851 1
1853 1
1875 1
1886 1
1888 1
1889 1
1891 2
1892 1
1893 5
1895 1
1896 2
1897 1
1899 6
1900 1
1901 2
1902 2
1903 2
1904 1
1905 1
1906 1
1907 3
1908 8
1909 3
1910 6
1924 1
1932 1
1933 1
1936 2
1937 2
1939 3
1941 1
1945 4
1946 5
1947 4
1948 5
1949 1
1950 5
1951 4
1952 3
1953 8
1954 5
1955 5
1956 6
1957 8
1958 5
1959 8
1960 7
1961 14
1962 10
1963 15
1964 8
1965 8
1966 11
1967 19
1968 14
1969 24
1970 19
1971 36
1972 23
1973 22
1974 32
1975 27
1976 39
1977 23
1978 38
1979 47
1980 51
1981 61
1982 64
1983 69
1984 73
1985 51
1986 75
1987 89
1988 108
1989 101
1990 101
1991 99
1992 90
1993 77
1994 93
1995 95
1996 100
1997 96
1998 90
1999 92
2000 98
2001 120
2002 126
2003 144
2004 125
2005 142
2006 149
2007 136
2008 170
2009 156
2010 158
2011 187
2012 194
2013 193
2014 201
2015 228
2016 206
2017 218
2018 235
2019 217
2020 234
2021 229
2022 197
2023 195
2024 215
2025 206
2026 191

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,612 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean williams m[au] (13,401 results)?
Vasopressors or Fluids in Early Septic Shock.
ARISE FLUIDS Investigators, the ANZICS Clinical Trials Group, and the ACEM Clinical Trials Network; Peake SL, Macdonald SPJ, Howe BD, Milford E, Jones P, Arendts G, Bailey M, Burcham J, Delaney A, Egerton-Warburton D, Fatovich D, Fraser JF, Higgins AM, Keijzers G, Udy AA, Williams P, Young PJ, Bellomo R; The ARISE FLUIDS Investigators, the ANZICS Clinical Trials Group, and the ACEM Clinical Trials Network. ARISE FLUIDS Investigators, the ANZICS Clinical Trials Group, and the ACEM Clinical Trials Network, et al. Among authors: williams p. N Engl J Med. 2026 Oct 8;395(14):1387-1398. doi: 10.1056/NEJMoa2516225. Epub 2026 Jun 11. N Engl J Med. 2026. PMID: 42274006 Clinical Trial.
Augmented Enteral Protein During Critical Illness: The TARGET Protein Randomized Clinical Trial.
Summers MJ, Chapple LS, Karahalios A, Bellomo R, Chapman MJ, Ferrie S, Finnis ME, French C, Hurford S, Kakho N, Maiden MJ, O'Connor SN, Peake SL, Presneill JJ, Ridley EJ, Tran-Duy A, Williams PJ, Young PJ, Zaloumis S, Deane AM; TARGET Protein Investigators and for the Australian and New Zealand Intensive Care Society Clinical Trials Group. Summers MJ, et al. Among authors: williams pj. JAMA. 2025 Jul 22;334(4):319-328. doi: 10.1001/jama.2025.9110. JAMA. 2025. PMID: 40495743 Free PMC article. Clinical Trial.
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade.
Hamidi H, Senbabaoglu Y, Beig N, Roels J, Manuel C, Guan X, Koeppen H, Assaf ZJ, Nabet BY, Waddell A, Yuen K, Maund S, Sokol E, Giltnane JM, Schedlbauer A, Fuentes E, Cowan JD, Kadel EE 3rd, Degaonkar V, Andreev-Drakhlin A, Williams P, Carter C, Gupta S, Steinberg E, Loriot Y, Bellmunt J, Grivas P, Rosenberg J, van der Heijden MS, Galsky MD, Powles T, Mariathasan S, Banchereau R. Hamidi H, et al. Among authors: williams p. Cancer Cell. 2024 Dec 9;42(12):2098-2112.e4. doi: 10.1016/j.ccell.2024.10.016. Epub 2024 Nov 21. Cancer Cell. 2024. PMID: 39577421 Free article.
Symptom-Based Dosing for Neonatal Opioid Withdrawal: The OPTimize NOW Randomized Clinical Trial.
Devlin LA, Babineau DC, Merhar SL, DeMauro SB, Kraft WK, Lorch SA, Das A, McDonald SA, Rhodes E, Schmidt AF, Trochinski L, Crawford M, Sithisarn T, Leeman L, Kovatis KZ, Ambalavanan N, Smith RW, Telang S, Tioseco JA, McAllister JM, Wexelblatt SL, Muniyappa B, Williams PK, Adeniyi-Jones SC, Hill CD, Wright T, Sokol GM, Johnson L, Hall RW, Duncan SD, Puopolo K, Dummula K, Anderson-Berry A, Davis JM, Poindexter B, Young LW; HEAL Evaluation of Limited Pharmacotherapies for Neonatal Opioid Withdrawal Syndrome (HELP for NOWS) Consortium. Devlin LA, et al. Among authors: williams pk. JAMA. 2026 Jun 23;335(24):2114-2125. doi: 10.1001/jama.2026.5782. JAMA. 2026. PMID: 42033722 Free PMC article. Clinical Trial.
Association of Phosphodiesterase-5 Inhibitor Treatment With Improved Survival in Pulmonary Hypertension Associated With COPD in the Pulmonary Vascular Research Institute GoDeep Meta-Registry.
Tello K, Yogeswaran A, Majeed RW, Kiely DG, Lawrie A, Brittain E, Annis JS, Olschewski H, Kovacs G, Hassoun PM, Balasubramanian A, Konswa Z, Sweatt AJ, Zamanian RT, Wilkins MR, Howard L, Arvanitaki A, Giannakoulas G, Cajigas HR, Frantz R, Williams PG, Frauendorf M, Marquardt K, Antoine T, Fuenderich M, Richter M, Grimminger F, Ghofrani HA, Wilhelm J, Seeger W; Pulmonary Vascular Research Institute GoDeep Consortium. Tello K, et al. Among authors: williams pg. Chest. 2025 Jan;167(1):224-240. doi: 10.1016/j.chest.2024.08.016. Epub 2024 Sep 7. Chest. 2025. PMID: 39182575 Free PMC article.
Confirmatory long-term efficacy and safety results of ataluren in patients with nmDMD from Study 041, an international, randomized, double-blind, placebo-controlled, Phase III trial.
Vlodavets D, Wu S, Kostera-Pruszczyk A, Chae JH, Gulati S, Shin JH, Lorentzos M, Cairns A, Jong YJ, Komaki H, Statland J, de Queiroz Campos Araujo AP, Gurgel-Giannetti J, Takeshima Y, Escobar Cedillo RE, Karachunski P, Haginoya K, Penematsa V, Chou C, Williams P, Werner C, McDonald CM. Vlodavets D, et al. Among authors: williams p. J Comp Eff Res. 2025 Oct;14(10):e240238. doi: 10.57264/cer-2024-0238. Epub 2025 Aug 22. J Comp Eff Res. 2025. PMID: 40843507 Free PMC article. Clinical Trial.
NMNAT2 is a druggable target to drive neuronal NAD production.
Tribble JR, Jöe M, Varricchio C, Otmani A, Canovai A, Habchi B, Daskalakis E, Chaleckis R, Loreto A, Gilley J, Wheelock CE, Jóhannesson G, Wong RCB, Coleman MP, Brancale A, Williams PA. Tribble JR, et al. Among authors: williams pa. Nat Commun. 2024 Jul 24;15(1):6256. doi: 10.1038/s41467-024-50354-5. Nat Commun. 2024. PMID: 39048544 Free PMC article.
6,612 results